NP 50301

Drug Profile

NP 50301

Alternative Names: iDESTRIN; NP50301

Latest Information Update: 03 Dec 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nonindustrial source
  • Developer Nascent Pharmaceuticals
  • Class Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Dry eyes

Most Recent Events

  • 04 Jan 2006 Data from a media release have been added to the adverse events and Eye disorders therapeutic trials sections
  • 16 Jun 2005 NP 50301 is available for licensing (http://www.nascentpharma.com)
  • 16 Jun 2005 Nascent Pharmaceuticals has completed enrolment in a phase IIb trial for dry eye syndrome in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top